Chinese biopharma stocks gain following report on proposed US trade rules

The short version

• Hong Kong-traded Chinese biotech stocks surged on Monday, with the Hang Seng Biotech Index rising over 5%.[CNBC]
• The gains followed reports that the U.S. Treasury Department is drafting rules to permit continued American investments and licensing in Chinese pharmaceuticals.[CNBC]
• Proposed exemptions will reportedly focus on bioweapon risks and dangerous pathogens.[CNBC]
• The proposed regulations are unfinalized and remain subject to alteration.[CNBC]

Key facts

• The Hang Seng Biotech Index rose over 5% on Monday, driven by stock surges from firms including Akeso, Innovent Biologics, and Sino Biopharmaceutical.[CNBC]
• The U.S. Treasury Department is drafting regulations that would permit U.S. firms to invest in Chinese drug developments, excluding weaponizable pathogens or biotechnology.[CNBC]
• Nomura data shows a record 81 licensing deals valued at $110 billion were completed between relevant firms in the first half of 2026.[CNBC]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Chinese biopharma stocks jump as U.S. weighs keeping door open to drug dealsCNBC